Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A legfontosabb adatok

Ki végzi
Jiangsu HengRui Medicine Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
82 fő vett részt
Kezdés
2024. jan. 15.
Befejezés
2025. febr. 17.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • HRG2005 inhalation
  • Placebo to match HRG2005 inhalation
  • Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
  • Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
A regiszteradat frissítve
2025. december 22.
Miért állt le
Sponsor's R\&D strategy adjusted.

Ki vehet részt

Életkor
40 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Able and willing to provide written informed consent and to comply with the study protocol
  • Subjects 40 years of age or older (inclusive), Male or female subjects
  • Subjects with an established clinical history of COPD
  • A post-bronchodilator FEV1/FVC ratio must be <0.7 at Screening and FEV1 must be <80% and ≥30% predicted normal at pre-randomization
  • a documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbation in the previous 12 months
  • Tobacco Use: Current or former smokers with a history of at least 10 pack-years of cigarette smoking
  • A score of ≥10 on the COPD Assessment Test (CAT) at pre-randomization

Ki nem vehet részt

  • Subjects who required systemic corticosteroids or antibiotics or hospitalized due to poorly controlled COPD or who had lower respiratory tract infections that required antibiotics within 4 weeks prior to Screening to pre-randomization
  • Subjects who had respiratory tract infections that required antibiotics within 2 weeks prior to Screening to pre-randomization
  • Subjects with lung volume reduction surgery within the 12 months prior to Screening
  • Subjects receiving oxygen therapy required for greater than 15 hours a day
  • Participation in clinical trials of any drug or medical device (except for screening failures) within 4 weeks before screening, or within 5 half-lives of the drug at screening (whichever is longer)
  • Subjects with other respiratory or respiratory related diseases, including but not limited to asthma, active tuberculosis, lung cancer, interstitial pulmonary disease, α1-antitrypsin deficiency, pulmonary heart disease, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease
  • Subjects who have Other known serious medical conditions;
  • Suspected allergy to any ingredient in the study drug
  • History of drug abuse within one year before screening
  • Other conditions judged by the investigator to be not suitable to participate in the trial
  • Subjects with significant laboratory abnormality at screening;
  • Clinically significant electrocardiogram abnormality;
  • Pregnant or lactating females

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease. Approximately 200 patients with moderate to severe COPD will be randomized into the study.

A vizsgálat 4 csoportja

  • Treatment group AA vizsgált kezelés

    Drug1 dose 1+Drug 3

    Kezelés: HRG2005 inhalation és Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

  • Treatment group BA vizsgált kezelés

    Drug1 dose 2+Drug 2+Drug 3

    Kezelés: HRG2005 inhalation, Placebo to match HRG2005 inhalation és Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

  • Treatment group CA vizsgált kezelés

    Drug1 dose 3+Drug 2+Drug 3

    Kezelés: HRG2005 inhalation, Placebo to match HRG2005 inhalation és Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

  • Treatment group DEgyéb csoport

    Drug 2+Drug 4

    Kezelés: Placebo to match HRG2005 inhalation és Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II, Randomized, Double Blind, Double Dummy, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A regiszteradat frissítve
2025. december 22.